Literature DB >> 29331768

The cholinergic anti-inflammatory pathway: an innovative treatment strategy for respiratory diseases and their comorbidities.

Mitsuhiro Yamada1, Masakazu Ichinose2.   

Abstract

Over the past few decades, it has been clarified that the nervous system and immune system have overlapping distributions and their interactions are critical in the regulation of immunological and inflammatory responses. The cholinergic anti-inflammatory pathway, including the parasympathetic nerve systems and humoral factors orchestrate the immune responses to protect the body during infection and tissue injury. Recent investigations have attempted to clarify how the parasympathetic nerve systems attenuate the systemic inflammatory responses and identified the α7 nicotinic acetylcholine receptor (α7nAChR) as a crucial target for attenuating the release of inflammatory cytokines from inflammatory cells including macrophages and dendritic cells. This modulatory circuit pathway possibly exists in the lungs and might be involved in regulating inflammation and immunity during infection and other inflammatory lung diseases including asthma and COPD, which means that modulation of the cholinergic anti-inflammatory pathway is a possible therapeutic target for lung diseases.
Copyright © 2018 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29331768     DOI: 10.1016/j.coph.2017.12.003

Source DB:  PubMed          Journal:  Curr Opin Pharmacol        ISSN: 1471-4892            Impact factor:   5.547


  19 in total

Review 1.  Airway Innervation and Plasticity in Asthma.

Authors:  L E M Kistemaker; Y S Prakash
Journal:  Physiology (Bethesda)       Date:  2019-07-01

2.  Cytokine Release Syndrome (CRS) and Nicotine in COVID-19 Patients: Trying to Calm the Storm.

Authors:  Jesus Gonzalez-Rubio; Carmen Navarro-Lopez; Elena Lopez-Najera; Ana Lopez-Najera; Lydia Jimenez-Diaz; Juan D Navarro-Lopez; Alberto Najera
Journal:  Front Immunol       Date:  2020-06-11       Impact factor: 7.561

3.  Augmentation of peripheral lymphocyte-derived cholinergic activity in patients with acute ischemic stroke.

Authors:  Meng Yuan; Bin Han; Yiping Xia; Ye Liu; Chunyang Wang; Chao Zhang
Journal:  BMC Neurol       Date:  2019-10-15       Impact factor: 2.474

4.  Nicotinic Cholinergic System and COVID-19: In Silico Identification of an Interaction between SARS-CoV-2 and Nicotinic Receptors with Potential Therapeutic Targeting Implications.

Authors:  Konstantinos Farsalinos; Elias Eliopoulos; Demetres D Leonidas; Georgios E Papadopoulos; Socrates Tzartos; Konstantinos Poulas
Journal:  Int J Mol Sci       Date:  2020-08-13       Impact factor: 5.923

Review 5.  COVID-19-related myocarditis and cholinergic anti-inflammatory pathways.

Authors:  Weike Liu; Zhendong Liu; Yue-Chun Li
Journal:  Hellenic J Cardiol       Date:  2020-12-08

6.  Response to the Comment on "A Systematic Review and Meta-Analysis of Hospitalised Current Smokers and COVID-19".

Authors:  Jesus González-Rubio; Carmen Navarro-López; Elena López-Najera; Ana López-Najera; Lydia Jiménez-Díaz; Juan D Navarro-López; Alberto Najera
Journal:  Int J Environ Res Public Health       Date:  2020-12-21       Impact factor: 3.390

7.  Feasibility of Therapeutic Effects of the Cholinergic Anti-Inflammatory Pathway on COVID-19 Symptoms.

Authors:  Roham Mazloom
Journal:  J Neuroimmune Pharmacol       Date:  2020-05-07       Impact factor: 4.147

Review 8.  Neuropeptides in asthma, chronic obstructive pulmonary disease and cystic fibrosis.

Authors:  Kalina R Atanasova; Leah R Reznikov
Journal:  Respir Res       Date:  2018-08-06

Review 9.  Nicotinic-nAChR signaling mediates drug resistance in lung cancer.

Authors:  Wan-Li Cheng; Kuan-Yuan Chen; Kang-Yun Lee; Po-Hao Feng; Sheng-Ming Wu
Journal:  J Cancer       Date:  2020-01-01       Impact factor: 4.478

10.  A Systematic Review and Meta-Analysis of Hospitalised Current Smokers and COVID-19.

Authors:  Jesus González-Rubio; Carmen Navarro-López; Elena López-Nájera; Ana López-Nájera; Lydia Jiménez-Díaz; Juan D Navarro-López; Alberto Nájera
Journal:  Int J Environ Res Public Health       Date:  2020-10-11       Impact factor: 3.390

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.